TOPLINE RESULTS FROM THE ALPINE 2/3 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING 3 DOSES OF THE FGF19 ANALOGUE ALDAFERMIN ON LIVER HISTOLOGY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND STAGE 2 OR 3 FIBROSIS

被引：0

作者：

Harrison, Stephen A. ^{[1
]}

Abdelmalek, Manal F. ^{[2
]}

Neff, Guy W. ^{[3
]}

Gunn, Nadege ^{[1
]}

Guy, Cynthia D. ^{[2
]}

Alkhouri, Naim ^{[4
]}

Bashir, Mustafa ^{[2
]}

Freilich, Bradley ^{[5
]}

Almeda, Jose ^{[6
]}

Knapple, Whitfield ^{[7
]}

Kohli, Anita ^{[4
]}

Khazanchi, Arun ^{[8
]}

Sheikh, Muhammad Y. ^{[9
]}

Leibowitz, Mark ^{[10
]}

Hogan, Reed ^{[11
]}

White, Judith ^{[12
]}

Kayali, Zeid ^{[13
]}

Rinella, Mary E. ^{[14
]}

Siddiqui, Mohammad S. ^{[15
]}

Kipnes, Mark ^{[16
]}

Moussa, Sam E. ^{[17
]}

Ortiz-Lasanta, Grisell ^{[18
]}

Poulos, John ^{[19
]}

Younes, Ziad ^{[20
]}

Bansal, Meena B. ^{[21
]}

Baum, Seth J. ^{[22
]}

Borg, Brian ^{[23
]}

Ruane, Peter J. ^{[24
]}

White, Alexander ^{[25
]}

Merkes, Kevin ^{[26
]}

Rashmee, Patil ^{[27
]}

Thuluvath, Paul J. ^{[28
,29
]}

Gottwald, Mildred ^{[30
]}

Khan, Mujib ^{[30
]}

Chen, Charles ^{[30
]}

Yan, Andrew Z. ^{[30
]}

Melchor-Khan, Liza ^{[30
]}

Chang, William ^{[30
]}

DePaoli, Alex ^{[30
]}

Ling, Lei ^{[30
]}

Lieu, Hsiao ^{[30
]}

机构：

[1] Pinnacle Clin Res, San Antonio, TX USA

[2] Duke Univ, Durham, NC USA

[3] Covenant Res & Clin, LLC, Sarasota, FL USA

[4] Arizona Liver Hlth, Chandler, AZ USA

[5] Kansas City Res Inst, Kansas City, MO USA

[6] Doctors Hosp Renaissance, Edinburg, TX USA

[7] Arkansas Gastroenterol, Hot Springs, AR USA

[8] Florida Res Inst, Bradenton, FL USA

[9] Fresno Clin Res Ctr, Fresno, CA USA

[10] Natl Res Inst, Delhi, NY USA

[11] GI Assoc & Endoscopy Ctr, Wausau, WI USA

[12] Bioclin Res, Princeton, NJ USA

[13] Inland Empire Liver Fdn, Rialto, CA USA

[14] Northwestern Univ, Evanston, IL USA

[15] Virginia Commonwealth Univ, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Richmond, VA USA

[16] Diabet & Glandular Dis Clin, San Antonio, TX USA

[17] Adobe Clin Res, Tucson, AZ USA

[18] Fdn Invest, San Juan, PR USA

[19] Cumberland Res Assoc, Cumberland, MD USA

[20] Gastro One, Germantown, TN USA

[21] Icahn Sch Med Mt Sinai, Dept Med, Div Liver Dis, New York, NY 10029 USA

[22] Excel Med Clin Trials, Boca Raton, FL USA

[23] Southern Therapy & Adv Res, Madison, NJ USA

[24] Ruane Clinical Res Grp Inc, Los Angeles, CA USA

[25] Progress Med Res, Port Orange, FL USA

[26] Alliance Clin Res, Alliance, OH USA

[27] South Texas Res Inst, Edinburg, TX USA

[28] Mercy Med Ctr, Baltimore, MD USA

[29] Univ Maryland, Sch Med, Baltimore, MD USA

[30] Ngm Biopharmaceut, San Francisco, CA USA

来源：

HEPATOLOGY | 2021年 / 74卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：5A / 6A

页数：2

共 50 条

[11] REGENERATE: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY OF OBETICHOLIC ACID THERAPY FOR NONALCOHOLIC STEATOHEPATITIS
Ratziu, V.
Sanyal, A. J.
MacConell, L.
Shringarpure, R.
Marmon, T.
Shapiro, D.
Younossi, Z. M.
JOURNAL OF HEPATOLOGY, 2016, 64 : S294 - S295
[12] Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis
Younossi, Zobair M.
Ratziu, Vlad
Sanyal, Arun J.
MacConell, Leigh
Shringarpure, Reshma
Marmon, Tonya
Shaprio, David
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S1273 - S1273
[13] Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
Stephen A. Harrison
Federico Perez Manghi
William B. Smith
Diana Alpenidze
Diego Aizenberg
Naomi Klarenbeek
Chi-Yi Chen
Eli Zuckerman
Eric Ravussin
Phunchai Charatcharoenwitthaya
Pin-Nan Cheng
Helena Katchman
Samuel Klein
Ziv Ben-Ari
Anisha E. Mendonza
Yiming Zhang
Miljen Martic
Shenglin Ma
Sheena Kao
Sandra Tanner
Alok Pachori
Michael K. Badman
YanLing He
Chinweike Ukomadu
Eric Sicard
Nature Medicine, 2022, 28 : 1432 - 1438
[14] Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
Harrison, Stephen A.
Manghi, Federico Perez
Smith, William B.
Alpenidze, Diana
Aizenberg, Diego
Klarenbeek, Naomi
Chen, Chi-Yi
Zuckerman, Eli
Ravussin, Eric
Charatcharoenwitthaya, Phunchai
Cheng, Pin-Nan
Katchman, Helena
Klein, Samuel
Ben-Ari, Ziv
Mendonza, Anisha E.
Zhang, Yiming
Martic, Miljen
Ma, Shenglin
Kao, Sheena
Tanner, Sandra
Pachori, Alok
Badman, Michael K.
He, YanLing
Ukomadu, Chinweike
Sicard, Eric
NATURE MEDICINE, 2022, 28 (07) : 1432 - +
[15] Effect of NGM282, an FGF19 Analogue, on Pruritus in Patients with Primary Sclerosing Cholangitis: Analysis of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Mayo, Marlyn J.
Ling, Lei
Hudgens, Stacie
Kim, Kathline H.
Hirschfield, Gideon
DePaoli, Alex
Beuers, Ulrich
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E151 - E151
[16] Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
Loomba, Rohit
Sanyal, Arun J.
Nakajima, Atsushi
Neuschwander-Tetri, Brent A.
Goodman, Zachary D.
Harrison, Stephen A.
Lawitz, Eric J.
Gunn, Nadege
Imajo, Kento
Ravendhran, Natarajan
Akahane, Takemi
Boone, Bradly
Yamaguchi, Masayuki
Chatterjee, Arkendu
Tirucherai, Giridhar S.
Shevell, Diane E.
Du, Shuyan
Charles, Edgar D.
Abdelmalek, Manal F.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (01) : 102 - 112
[17] Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
Stephen A. Harrison
Rebecca Taub
Guy W. Neff
K. Jean Lucas
Dominic Labriola
Sam E. Moussa
Naim Alkhouri
Mustafa R. Bashir
Nature Medicine, 2023, 29 : 2919 - 2928
[18] Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
Harrison, Stephen A.
Taub, Rebecca
Neff, Guy W.
Lucas, K. Jean
Labriola, Dominic
Moussa, Sam E.
Alkhouri, Naim
Bashir, Mustafa R.
NATURE MEDICINE, 2023, 29 (11) : 2919 - 2928
[19] NGM282, an engineered analogue of FGF19, significantly improves markers of bile acid synthesis, hepatic injury and fibrosis in PSC patients: Results of a phase 2, multicenter, randomized, double-blind, placebo-controlled trial
Hirschfield, G.
Chazouilleres, O.
Drenth, J. Ph
Thorburn, D.
Harrison, S.
Landis, C.
Mayo, M. J.
Muir, A.
Trotter, J. F.
Karsdal, M.
Jaros, M.
Ling, L.
Kim, K. H.
Rossi, S.
Somaratne, R. M.
Depaoli, A.
Beuers, U.
JOURNAL OF HEPATOLOGY, 2018, 68 : S101 - S101
[20] Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
Hordinsky, Maria
Hebert, Adelaide A.
Gooderham, Melinda
Kwon, Ohsang
Murashkin, Nikolay
Fang, Hong
Harada, Kazutoshi
Law, Ernest
Wajsbrot, Dalia
Takiya, Liza
Zwillich, Samuel H.
Wolk, Robert
Tran, Helen
PEDIATRIC DERMATOLOGY, 2023, 40 (06) : 1003 - 1009

← 1 2 3 4 5 →